Non-Hodgkin Lymphoma
Conference Coverage
Combo can produce durable remissions in PTCL
Photo by Larry Young SAN FRANCISCO—A combination treatment regimen can produce durable remissions in patients newly diagnosed with peripheral T-...
Conference Coverage
Chemo regimen can be ‘highly effective’ against ENKTL
Photo by Larry Young SAN FRANCISCO—A 3-agent chemotherapy regimen can be “highly effective” in patients with extranodal natural killer/T-cell...
Conference Coverage
Dual inhibitor could treat ATLL
Photo by Larry Young SAN FRANCISCO—Preclinical research suggests a compound that inhibits both EZH1 and EZH2 could be effective against adult T-...
Conference Coverage
Immunotherapy proves active against MF, SS
Photo by Larry Young SAN FRANCISCO—The PD-1-blocking antibody pembrolizumab can produce “significant objective clinical responses” in patients...
Conference Coverage
Mutations may impact response to HDACis in PTCL-NOS
Photo by Larry Young SAN FRANCISCO—Preclinical research has revealed mutations that may affect the performance of histone deacetylase inhibitors...
Conference Coverage
Lenalidomide shows promise for treating ATLL
Photo by Larry Young SAN FRANCISCO—Results of a phase 2 trial suggest lenalidomide may be a treatment option for patients with relapsed adult T-...
Conference Coverage
Study suggests chidamide could treat rel/ref CTCL too
Photo by Larry Young SAN FRANCISCO—The oral histone deacetylase inhibitor chidamide can elicit responses in patients with relapsed or refractory...
News
NICE issues draft guideline for NHL
a cancer patient Photo courtesy of NCI/ Mathews Media Group The National Institute for Health and Care Excellence (NICE) has issued a draft...
News
New insight into CLL development
Photo by Graham Colm New research indicates that chronic lymphocytic leukemia (CLL) can develop during nearly any stage of B-cell maturation....
News
Drug granted another breakthrough designation for CLL
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to the BCL-2 inhibitor venetoclax when given with rituximab...
News
FDA approves maintenance therapy for CLL
Photo courtesy of GSK The US Food and Drug Administration (FDA) has approved the use of ofatumumab (Arzerra) as maintenance therapy for patients...